Send us Fan Mail

🧠 Hidden epidemic:

50–70% of premenopausal women have iron deficiency.

Also common in CKD, GI bleeding, chronic disease.

🔍 Diagnosis Pearls:

Ferritin cutoff: <30 ng/mL (not 20!) for iron deficiency.

RLS patients: target ferritin >75.

Consider retic count: low = underproduction; high = bleeding/hemolysis.

💊 Treatment Tips:

Oral iron: ferrous sulfate preferred; daily dosing > TID.

Take with meat or vitamin C, avoid calcium or tea.

Alternate-day dosing may reduce GI side effects (but tricky compliance).

IV iron if oral not tolerated or patient is inflamed.

🧩 Clinical Takeaway:

Check for functional iron deficiency in inflammatory states.

Choose IV formulations based on cost, availability, and dosing frequency.

Send us Fan Mail

🧠 Clinical Problem:

HFpEF (Heart Failure with Preserved EF) has lacked effective, proven therapies.

Finerenone (non-steroidal MRA) offers new hope.

🧪 FINEARTS-HF Trial:

6,000+ patients with EF ≥40%, followed for ~32 months.

Compared Finerenone vs placebo.

📈 Results:

↓ Heart failure hospitalization significantly.

No significant reduction in CV mortality.

Hyperkalemia: 9.7% (Finerenone) vs 4.2% (Placebo).

🧩 Clinical Takeaway:

May offer benefit for HFpEF — especially if SGLT2i also used.

Expensive; Spironolactone may be a lower-cost alternative with similar benefit.

Important addition to the limited HFpEF toolbox.

Send us Fan Mail

🧠 Clinical Context

Fever is known to be associated with worse neurologic outcomes in stroke, both ischemic and hemorrhagic. Intuitively, preventing fever seems like a slam-dunk goal, right? This study took that theory to trial, literally.

🧪 Study Highlights: The INTREPID Trial

• Design: Open-label, randomized controlled trial with blinded outcome assessment
• Setting: 43 ICUs across 7 countries
• Participants: 686 critically ill stroke patients (254 ischemic, 223 ICH, 200 SAH)
• Intervention:
  • Fever prevention group: Surface cooling via automated gel pads, targeted at 37.0°C
  • Standard care group: Fever treatment only when temps hit ≥38.0°C
• Duration: Cooling maintained for 14 days or until ICU discharge

📈 Outcomes

• Primary:
  • Fever burden significantly reduced in the cooling group: 0.37 vs 0.73 °C-hour (P < .001)
  • Greatest fever reduction seen in ICH and SAH subtypes
• Secondary (Functional):
  • No difference in 3-month Modified Rankin Scale (mRS median = 4 in both groups)
  • Odds ratio for favorable shift: 1.09 (P = .54) — not statistically significant
• Adverse Events:
  • Higher total AEs in the cooling group (82% vs 76%)
  • Similar rates of infections, cardiac, and respiratory complications

⚠️ Caveats

• Trial halted early due to futility in primary functional outcome
• No significant improvement in functional recovery
• Fever control alone may not be enough — context and patient-specific variables likely matter

🧩 Clinical Takeaway

Cooling blankets do reduce fever after stroke, but don’t translate to better outcomes. Despite intuitive appeal and clear thermal control, the mRS at 3 months didn’t budge.

🏛️ Functional recovery from stroke remains complex. It's not just about temperature — we may need to refine who benefits and how we target them. More nuanced strategies are still needed.

Send us Fan Mail

🧠 Clinical Myth:

“Delay levodopa to delay motor complications.”

🧪 LEAP Trial (Levodopa in Early Parkinson’s):

Compared early start vs 40-week delayed start.

5-year follow-up showed no difference in motor fluctuations or dyskinesia.

📈 Key Outcomes:

Early levodopa = better function earlier, no long-term harm.

Wearing off effect was similar in both groups.

🧩 Clinical Takeaway:

Don’t hold back levodopa if patient is symptomatic.

Starting early improves quality of life without hastening decline.

Personalize the approach — don’t delay just for dogma.

Send us Fan Mail

🧠 Clinical Question:

Are we overtreating bloodstream infections with 14-day regimens?

🧪 Study Overview:

Multicenter RCT in ICU/inpatient settings (7 vs 14 days of antibiotics).

Excluded: Immunosuppressed, endocarditis, Staph aureus, and infections needing longer therapy.

📈 Findings:

No difference in 90-day mortality or relapse.

More C. diff and drug reactions in the 14-day group.

🧩 Clinical Pearls:

7 days is sufficient for most uncomplicated bacteremia.

Reserve 14+ days for Staph aureus, endocarditis, or deep-seated infections.

Fewer days = lower risk, lower cost, faster discharge.

Send us Fan Mail

🧠 Clinical Context:

Historically, breast cancer treatment has included radical mastectomies and full axillary dissections.

New data supports less invasive approaches for specific low-risk populations.

🧪 The SOUND Trial (and similar studies):

T1–T2 tumors (≤5 cm), clinically node-negative, ER+.

Compared no axillary surgery vs sentinel lymph node biopsy.

No difference in outcomes, but significantly less pain, lymphedema, and improved arm mobility in the non-surgical group.

🧩 Clinical Takeaway:

In selected ER+ patients with negative axillary imaging, sentinel lymph node biopsy may be safely omitted.

Shifts the focus to preserving quality of life without compromising survival.

The art of modern oncology = doing less, better.

Send us Fan Mail

🧠 Clinical Background:

Inflammation plays a big role in atherothrombosis.

Colchicine — an old gout drug — shows promise in CV risk reduction.

🧪 COLCOT Trial:

Colchicine 0.5 mg daily post-MI.

Greatest benefit in patients with type 2 diabetes.

📈 Outcomes:

Reduced MACE (MI, stroke, death) in diabetics.

Adverse Effects: Nausea, diarrhea, ↑ risk of pneumonia (unclear why).

🧩 Clinical Takeaway:

Consider colchicine in diabetics post-MI or with recurrent ACS.

Cheap, oral, and anti-inflammatory — a new use for an old drug.

Send us Fan Mail

🧠 Clinical Context:

Hypertrophic obstructive cardiomyopathy (HOCM): Genetic disorder causing LVOT obstruction.

Traditionally managed with BBs, CCBs, disopyramide… or surgery.

💊 Drug: Mavacamten (Cardiac Myosin Inhibitor)

Targets sarcomeric hypercontractility directly.

FDA approved for NYHA Class II–III obstructive HCM.

🧪 EXPLORER-HCM Trial:

62-week follow-up:

↓ LVOT gradient (resting & post-exercise).

Improved NYHA class.

↑ Peak oxygen consumption (VO₂).

⚠️ Key Considerations:

Follow-up echocardiograms required — risk of LVEF drop.

Avoid negative inotropes.

Can worsen HF if EF <55%.

🧩 Clinical Takeaway:

First disease-modifying med for obstructive HCM.

Exercise no longer strictly off-limits — patients should be supervised and tailored.

If surgery is needed, refer to high-volume HCM centers only.

Send us Fan Mail

🧠 Clinical Problem:

Behavioral disturbances in Alzheimer’s are notoriously hard to treat.

Guidelines tell us: “Don’t use antipsychotics” — but what do you do at 2AM when Nana's throwing punches?

💊 Study Overview:

345 patients, moderate-severe Alzheimer’s + aggressive agitation.

Brexpiprazole 2–3 mg daily vs placebo.

Dosing didn’t differ much in effect.

📈 Outcomes:

Significant reduction in agitation inventory scores in brexpiprazole group.

Well tolerated; most common side effect: headache (7%).

⚠️ Caveats:

Costly medication.

Atypical antipsychotic — still carries black box warning for mortality in dementia.

🧩 Clinical Takeaway:

Brexpiprazole may offer a much-needed option in patients with severe behavioral disturbances.

Not for mild sundowning — reserve for safety-critical scenarios.

Discuss risks/benefits carefully with family or POA.

Send us Fan Mail

🧠 Clinical Question:

What's the optimal hemoglobin threshold for transfusion post-MI?

Old dogma: “Keep Hgb >10”.

New data: Less might be just as safe.

🧪 The MINT Trial (Myocardial Ischemia & Transfusion):

Compared liberal (Hgb <10) vs restrictive (Hgb <8) transfusion strategies.

Lower 30-day recurrent MI or cardiac death seen with Hgb ≥10 approach.

But... secondary analysis showed no major difference between 9 vs 10.

⚠️ Risks of Transfusion:

Volume overload (TACO).

Hemolytic and allergic reactions.

Cost and hospital stay increase.

🧩 Clinical Takeaway:

Consider transfusing at Hgb 9–10 in post-MI, particularly if symptoms or hemodynamics justify it.

Be cautious, but not rigid — individualize based on patient condition.